Interesting, page-1707

I’m only going from what’s presented in the videos and my understanding from what’s presented - so of course DYOR

there are others who would be better informed than myself like @Rustydog62 who has followed this for much longer , or those with some medical background like @shanni all appreciated to help the forum get good balance and footing .

my perspective however tries to focus on what metrics I see as relevant to reprice this in market perception and risk weight balance

what is new in 30 years of imaging?

MRX. That’s where the real game changer is .
if we can fit this into the diagnostic standard of care - it’s a numbers game . How many people will opt for this into the standard of their care ? Who wants an unnecessary biopsy ? When MRX will be a non invasive interim step ?

volumes of NP , through All the above irons in the fire - is entree, main meal , and supper . That’s the nature of the blue sky - the market will price this at a slice of that pre trial IMO